Emendo Biotherapeutics Raises $61 Million to Advance Next Generation Genome Editing Therapeutics
15.1.2020 14:00:00 EET | Business Wire | Press release
Emendo Biotherapeutics, a leader in next-generation gene editing using synthetic biology to address untreatable diseases, today announced a Series B investment totaling $61 million led by AnGes, Inc., a Japan-based biopharma, reflecting its strategic interest in partnering with Emendo on the development of specific indications.
“This financing provides a strong foundation from which we can accelerate our proprietary OMNI gene editing platform towards a broad clinical pipeline for addressing devastating untreatable diseases,” said Dr. David Baram, President & CEO, Emendo Biotherapeutics. “We are grateful for such strong support from so many high-quality investors and strategic partners including AnGes, OrbiMed Advisors, OrbiMed Israel Partners and Takeda Ventures who share our vision to translate this powerful science into transformative medicines.”
Emendo Biotherapeutics is pioneering OMNI, a next-generation allele-specific gene editing platform that uses synthetic biology to expand what is possible in genome-editing. In 2019, Emendo granted an option to Takeda to use the OMNI nuclease gene editing program for two research and development targets. Emendo received an undisclosed investment from Takeda Ventures that was converted in the Series B.
Emendo’s OMNI technology enables precision gene editing while maintaining high efficiencies, uniquely addressing dominant indications such as Severe Congenital Neutropenia (SCN), caused by mutations in the neutrophil elastase gene ELANE. Dominant indications represent the vast majority of genetic diseases which until now have been untreatable.
About AnGes
AnGes is a Tokyo and Osaka, Japan-based biopharmaceutical company focused on the development and commercialization of gene-based medicines including gene therapy and oligonucleotide molecules. AnGes’ lead product HGF plasmid, which received conditional approval in Japan in 2019, is a DNA plasmid which encodes the human Hepatocyte Growth Factor (HGF) gene, an angiogenic (new blood vessel growth) factor for critical limb ischemia (CLI). The company is also developing NF-kB Decoy oligonucleotide for the treatment of inflammatory diseases. For more information please visit www.anges.co.jp.
About Emendo
Emendo Biotherapeutics is transforming the landscape of genome-editing based medicine through its use of novel CRISPR nucleases, advanced cutting-edge protein engineering platforms, diverse pipeline of clinical programs and extensive intellectual property portfolio. For more information please visit us at www.emendobio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005379/en/
Contact information
Julie Amar
info@emendobio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Brings Real Device Testing to Kane CLI, Letting Developers Test Mobile Apps on Real Phones From Any Terminal16.10.2026 17:00:00 EEST | Press release
TestMu AI (formerly LambdaTest), the Full Stack Agentic AI Quality Engineering platform, announced real device support in Kane CLI. Developers can now test a mobile app on a real phone or tablet in the TestMu AI cloud straight from the terminal: they type what to test in plain English, and Kane taps through the app on a real Android or iOS device. Until now, testing a mobile app on real hardware meant keeping a drawer of phones, or a separate device farm outside the developer's workflow. With real device support, Kane CLI removes that dependency again now by giving terminal-first access to the real device cloud. Kane CLI on real devices gives teams: Real Android and iOS devices from any terminal. Kane CLI opens a real device in the TestMu AI cloud and taps through the app from natural language prompts. Developers pick a model and OS version, or let the cloud assign any available device. A live view of the device. The real device's screen opens in its own window on the developer's lapto
Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World16.10.2026 17:00:00 EEST | Press release
Abu Dhabi has launched TAMM Global, a private technology company established to make the award-winning technology behind TAMM available to governments worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016490320/en/ Abu Dhabi Launches TAMM Global to Bring Its AI-Native Government Platform to the World (Photo: AETOSWire) It is the first time the AI-powered platform, which serves 4.7 million users and is recognized as one of the world’s most advanced digital government platforms, will be available for international licensing and deployment. The launch marks a significant milestone in Abu Dhabi’s ambition to become the world’s first AI-native government. It reflects growing international demand for proven technologies that can accelerate digital transformation while protecting sovereignty, regulatory compliance and public trust. It also demonstrates how homegrown innovation and intellectual property are creating oppor
METI and GX Acceleration Agency will hold GGX Finance Summit 202616.10.2026 16:00:00 EEST | Press release
On Monday, October 26th, the Ministry of Economy, Trade and Industry (METI) and GX Acceleration Agency will hold the GGX (Global GX) Finance Summit at Tokyo Prince Hotel and online. The Summit will advance discussions on transition finance, industry decarbonization, and the role of business and finance in driving decarbonization. It will also promote cooperation among government, industry, and the financial sector, and lead international rulemaking toward achieving both emission reductions and economic growth. Outline of GGX Finance Summit Date: October 26th, 2026 10:00 - 16:20 (JST, GMT+9:00) Venue: Tokyo Prince Hotel (Tokyo) (3-3-1 Shiba-Koen, Minato-ku, Tokyo 105-8560, Japan) Organizer: Ministry of Economy, Trade and Industry (METI), GX Acceleration Agency Co-organizer: GX Future Consortium Format: Hybrid (On-site and on-line) Language: Japanese/English (with English/Japanese simultaneous interpretation) Press Registration Please complete your registration by accessing the official
Dubai Culture: Dubai Ranks First Globally in Attracting New FDI Projects in Cultural and Creative Industries in 202516.10.2026 14:32:00 EEST | Press release
Dubai Culture and Arts Authority has revealed that Dubai retained its position as the world’s leading destination for new foreign direct investment (FDI) projects in the cultural and creative industries (CCIs) in 2025, ranking first globally for the fourth consecutive year. According to data from the Financial Times’ fDi Markets, a leading source of greenfield FDI intelligence, Dubai topped the ranking of 233 cities, ahead of London, Singapore, Riyadh and Bengaluru. The results reflect the strength of the emirate’s investment environment and its appeal to creative businesses, investors, entrepreneurs and talent from around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261016681830/en/ Dubai Culture: Dubai ranks first globally in attracting new FDI projects in cultural and creative industries in 2025 (Graphic: AETOSWire) In 2025, Dubai attracted 754 new projects in the cultural and creative industries, with greenf
Horizon3 and Pax8 Expand Partnership to Bring Autonomous Security Testing to MSPs Across Europe16.10.2026 09:03:00 EEST | Press release
Horizon3, the AI-Native Proactive Security Company, today announced the expansion of its Pax8 partnership across Europe, bringing the NodeZero® Proactive Security Platform to the region’s managed service providers (MSPs) through the Pax8 Marketplace. The expansion enables partners to build recurring security services that help small and midsized businesses understand how attackers could compromise their environments, prioritize corrective actions, and verify remediation. Building on the companies’ North American marketplace launch, the European expansion makes autonomous offensive security testing accessible to more MSPs and the businesses they protect. Partners can use NodeZero to deliver initial assessments, support remediation engagements, and establish ongoing testing programs without conducting every penetration test manually. “MSPs are accountable for protecting their customers’ security, but a list of vulnerabilities does not tell them what is actually exploitable, and their lev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom